Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trialSanjay Ramakrishnan, Mona Bafadhel, Nabil T. Fadai et al.|The Lancet Respiratory Medicine|2021Cited by 434
Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trialSanjay Ramakrishnan, Mona Bafadhel, Richard Russell et al.|The Lancet Respiratory Medicine|2024Cited by 98
Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trialSanjay Ramakrishnan, Mona Bafadhel, Helen Jeffers et al.|The Lancet Respiratory Medicine|2023Cited by 70
Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysisJonathan Baker, Mona Bafadhel, Mahdi Mahdi et al.|The Lancet Respiratory Medicine|2022Cited by 58
Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trialSanjay Ramakrishnan, Mona Bafadhel, Dan V. Nicolau et al.|medRxiv|2021Cited by 25